Anti-tumor efficacy of Centchroman formulated as niosomes and gel implant was evaluated in Swiss albino mice bearing Ehrlich ascites carcinoma at 10 mg/kg body weight dose given subcutaneously. Median day of death, percentage increase in host life span and changes in body weight were studied. Centchroman significantly (p<0.05) increased the median day of death both in free and formulated systems. Also, injectable formulations exhibited a significant (p<0.05) increase in host life span compared to free drug, hence, enhanced anti-tumor efficacy against Ehrlich ascites carcinoma.
|Number of pages||4|
|Journal||Indian Journal of Physiology and Pharmacology|
|Publication status||Published - 04-1999|
All Science Journal Classification (ASJC) codes